FierceBiotech Radio on Gilead's maxed-out revenue and BioMarin's FDA struggles

In an episode free of Valeant Pharmaceuticals ($VRX) and Martin Shkreli, FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss a Senate investigation into Gilead Sciences' ($GILD) pricing of the hepatitis C drug Sovaldi, BioMarin's ($BMRN) efforts to win approval for a rare disease treatment and GlaxoSmithKline's latest woes in China.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to radio@fiercebiotech.com.

Read more on